Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical CoCHGCF -2.43%85 Cash Ratio is 2.45 as of Jun. 2026, which is 24% above its 10-year median of 1.97. GuruFocus rates CHGCF with a GF Score™ of 85/100 and a GF Value™ of $47.53 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 975 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks better than 82.56% on this metric.
Chugai Pharmaceutical Co has a Cash Ratio of 2.45. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Chugai Pharmaceutical Co's Cash Ratio or its related term are showing as below:
CHGCF'
s Cash Ratio Range Over the Past 10 Years
Min: 1.19 Med: 1.97 Max: 4.53
Current: 2.45
During the past 13 years, Chugai Pharmaceutical Co's highest Cash Ratio was 4.53. The lowest was 1.19. And the median was 1.97.
CHGCF's Cash Ratio is ranked better than 82.56% of 975
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs CHGCF: 2.45
Chugai Pharmaceutical Co (OTCPK:CHGCF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Chugai Pharmaceutical Co Cash Ratio Related Terms
Chugai Pharmaceutical Co Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co (CHGCF) has a Cash Ratio of 2.45 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Chugai Pharmaceutical Co and its competitors. This is 24% above median its historical median of 1.97. Over the past decade, Chugai Pharmaceutical Co's Cash Ratio has ranged from 1.19 to 4.53. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #170 out of 975 companies in the Drug Manufacturers industry, placing it in the top 17.4%.
Is Chugai Pharmaceutical Co's Cash Ratio too high?
Chugai Pharmaceutical Co's current Cash Ratio of 2.45 is 24% above median its 10-year median of 1.97. Over the past 10 years, this metric has ranged from a low of 1.19 to a high of 4.53. The Drug Manufacturers industry median Cash Ratio is 0.60. Chugai Pharmaceutical Co's value of 2.45 is 308.3% above this industry median. Based on the distribution chart, Chugai Pharmaceutical Co ranks #170 out of 975 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Chugai Pharmaceutical Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Cash Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #170 out of 975 companies for Cash Ratio. This places Chugai Pharmaceutical Co in the top 17% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.60. Chugai Pharmaceutical Co's value of 2.45 is 308.3% above this benchmark. Historically, Chugai Pharmaceutical Co's own Cash Ratio has ranged from 1.19 to 4.53 over the past decade. While the company's 10-year median is 1.97 vs. the industry median of 0.60, Chugai Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.60, based on 975 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chugai Pharmaceutical Co's current Cash Ratio of 2.45 is 308.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Chugai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current Cash Ratio is 2.45, which is 24% above median its own 10-year median of 1.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (CHGCF) is currently considered Modestly Undervalued. The stock's GF Value™ is $47.53, compared to a current price of $41.27 — trading 13.2% below its estimated fair value. The current Cash Ratio is 2.45, which is 24% above median its 10-year median of 1.97 and 308.3% above the Drug Manufacturers industry median of 0.60. Chugai Pharmaceutical Co's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Chugai Pharmaceutical Co (CHGCF), the current Cash Ratio is 2.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (CHGCF) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of $41.27 is trading 13.2% below its estimated GF Value™ of $47.53.
GuruFocus considers Chugai Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for CHGCF:
Cash Ratio: 2.45 (24% above median its 10-year median of 1.97)
GF Value™: $47.53 vs. price of $41.27 (13.2% below fair value)
Industry Position: 308.3% above the Drug Manufacturers median (#170 of 975)
No single metric tells the full story. See the CHGCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
85GF Score
Get the complete analysis for CHGCF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHGCF has been successfully added to your 
